Fig. 4From: Outcomes with sequential FLT3-inhibitor-based therapies in patients with AMLThe median OS in cohort 2 (relapsed/refractory) by sequence of FLT3i exposure (a), and treatment modality (b–d) (single-agent FLT3i vs. combination)Back to article page